First Individualized Neoantigen Therapy Meets Phase 3 Endpoints in Melanoma

Merck and Moderna’s individualized neoantigen therapy intismeran, given with KEYTRUDA after surgery, has become the first regimen to show a clinically meaningful improvement over KEYTRUDA alone in patients with resected high-risk melanoma. The Phase 3 INTerpath-001 trial met its primary endpoint of recurrence-free survival and a key secondary endpoint of distant metastasis-free survival, the companies announced on 19 August 2026.

Intismeran autogene (also known as V940 or mRNA-4157) is built from a sample of each patient’s tumor. The therapy reads the unique mutations in the cancer and uses synthetic mRNA coding for up to 34 neoantigens to train the immune system to attack those cells. Every dose is made for a single patient.

The result is the first positive Phase 3 readout for an individualized neoantigen therapy, the first for an mRNA-based cancer therapy, and the first Phase 3 study to show a clinically meaningful improvement over KEYTRUDA alone in the adjuvant melanoma setting. Adjuvant therapy is given after surgery to lower the chance the cancer returns.

Ad

Trial design and outcomes

INTerpath-001 (NCT05933577) enrolled 1,137 patients with completely resected stage IIB, IIC, III or IV cutaneous melanoma who had not received prior systemic therapy. Patients were randomized 2:1 to receive intismeran (1 mg every three weeks for up to nine doses) with KEYTRUDA (400 mg every six weeks for up to nine cycles) or KEYTRUDA alone for about a year.

At a pre-specified interim analysis, the combination showed statistically significant and clinically meaningful improvements in both recurrence-free survival and distant metastasis-free survival compared with KEYTRUDA alone. The safety profile matched earlier studies of the combination, with no new safety signals. The trial is continuing to evaluate overall survival and other key secondary endpoints.

The readout builds on Phase 2b data from KEYNOTE-942 (mRNA-4157-P201). At five years of follow-up, presented at the 2026 ASCO annual meeting, the combination reduced the risk of recurrence or death by 49% (hazard ratio 0.51; 95% CI 0.294 to 0.887) and the risk of distant metastasis or death by 59% (hazard ratio 0.411; 95% CI 0.200 to 0.843) compared with KEYTRUDA alone.

Market access for an individualized neoantigen therapy

For payers and health technology assessment bodies, the clinical signal is now clear. The open question is how to value a medicine that is manufactured for one patient at a time.

Individualized neoantigen therapies carry a cost structure unlike a conventional drug. Each treatment needs a tumor sample, genomic sequencing, and a bespoke manufacturing run, which raises questions about price, turnaround time, and how such a product fits standard reimbursement and value-assessment frameworks. A therapy that keeps patients cancer-free for longer could offset downstream costs, but the evidence for long-term benefit, including overall survival, is still developing.

Merck and Moderna plan to present the data at an upcoming international medical meeting and to engage with regulators on filing submissions. How the therapy is priced and reimbursed will matter as much as the efficacy result in deciding whether it reaches the patients who could benefit.

A wider program

The companies are running the INTerpath program across nine Phase 2 and Phase 3 trials in melanoma, non-small cell lung cancer, bladder cancer and renal cell carcinoma, testing intismeran with KEYTRUDA and other anti-cancer therapies, and on its own.

Melanoma is a disease where recurrence after surgery remains a real risk. More than 330,000 new cases were diagnosed worldwide in 2022, and the US alone is expected to record about 112,000 new cases and over 8,500 deaths in 2026. Most recurrences are metastatic rather than localized, and they usually appear within the first two years.